Compare LEXX & APYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEXX | APYX |
|---|---|---|
| Founded | 2004 | 1982 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5M | 143.2M |
| IPO Year | N/A | 1987 |
| Metric | LEXX | APYX |
|---|---|---|
| Price | $0.62 | $3.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.00 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 1.3M | 72.0K |
| Earning Date | 01-09-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $705,923.00 | ★ $47,902,000.00 |
| Revenue This Year | $13.35 | $8.50 |
| Revenue Next Year | $78.83 | $7.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 52.05 | N/A |
| 52 Week Low | $0.48 | $0.76 |
| 52 Week High | $2.43 | $4.44 |
| Indicator | LEXX | APYX |
|---|---|---|
| Relative Strength Index (RSI) | 33.25 | 44.67 |
| Support Level | $0.48 | $3.46 |
| Resistance Level | $0.70 | $3.70 |
| Average True Range (ATR) | 0.12 | 0.16 |
| MACD | -0.06 | -0.07 |
| Stochastic Oscillator | 15.07 | 24.29 |
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.